A Memorial Sloan Kettering phase 1 clinical trial revealed an immune response in some pancreatic cancer patients. Study co-author Dr. Vinod Balachandran talks about the impact on future cancer care.

Many vaccines are inherently safe and do not require phase I dose finding trials. Patients with advanced cancers and compromised immune systems are not good candidates for assessing either the ...

January 1, 2007 (Vol. 27, No. 1) VC Hesitation Is Largely Unfounded Safety and quality of life are becoming more important to patients, and because of this the field of therapeutic cancer vaccines ...

A number of clinical trials are looking at vaccines as a breast cancer treatment option and at biomarkers as a way to guide treatment decisions. Vaccines for Breast Cancer ...

We could be on the verge of a major cancer treatment breakthrough, with a new vaccine shown to completely obliterate pancreatic cancer cells in preclinical trials. This paves the way for it to ...

In their recently published JAMA Oncology study, the CVI team showed promising results from a phase I nonrandomized clinical trial for a breast cancer vaccine in advanced stage HER2-positive breast ...

An experimental approach to treating pancreatic cancer with the messenger RNA (mRNA)-based therapeutic cancer vaccine autogene cevumeran continues to show potential to stimulate an immune response ...

More information: Vvax001, a therapeutic vaccine for patients with HPV16-positive high-grade cervical intraepithelial ...

The Oxford team developed a two-dose therapeutic cancer vaccine, ... a Phase 1/2a clinical trial is set to begin later this year, in 80 patients with non-small cell lung cancer.

The use of vaccines not to prevent illness but as treatments, rallying the immune system to attack existing tumours, has the potential to revolutionize cancer therapy. Produced with support from ...

Ninety mRNA-based therapeutic cancer vaccines tested in clinical trials since 2000 were listed in findings published in January in Heliyon — with 33 trials having started since 2020 and researchers ...